Study record · NAD+
Intravenous infusion of NAD+ versus nicotinamide riboside: retrospective tolerability pilot
IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.
Key result
IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.
Study details
Study designRetrospective real-world comparative pilot
PopulationCommercial-clinic clients receiving IV NAD+ or IV nicotinamide riboside
Sample sizeNot stated here
RouteIntravenous
Regimen / exposure500 mg daily for four consecutive days
Duration4 days + 30-day follow-up
ComparatorIV nicotinamide riboside
Primary endpoint / questionInfusion tolerability, vital signs, laboratory safety markers and exploratory metabolic biomarkers
Safety resultModerate-to-severe GI symptoms, increased heart rate and chest pressure occurred during NAD+ infusions and resolved when infusions ended.
Key limitationsRetrospective, small, commercial setting, non-randomized; not an efficacy trial for anti-ageing, energy or cognition.
Registry / identifierPMID 41704678